RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Freeline Therapeutics Holdings - Stock

Freeline Therapeutics Holdings ROA 2024

Freeline Therapeutics Holdings ROA

-1.03

Ticker

FRLN

ISIN

US35655L1070

WKN

A2QADU

In 2024, Freeline Therapeutics Holdings's return on assets (ROA) was -1.03, a 3.26% increase from the -0.99 ROA in the previous year.

Freeline Therapeutics Holdings Aktienanalyse

What does Freeline Therapeutics Holdings do?

Freeline Therapeutics Holdings PLC is a biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company was founded in 2015 and is headquartered in London, United Kingdom. Freeline Therapeutics also has a branch in Munich, Germany. The company focuses on the development and manufacturing of gene therapies using AAV (Adeno-associated viruses) vectors. These vectors serve as delivery vehicles to transport therapeutic genes into cells. Freeline Therapeutics utilizes its expertise in this field to develop innovative gene therapies for patients with rare diseases. Freeline Therapeutics' business model is based on researching, developing, and commercializing gene therapies for rare diseases. The company has several partnerships with other biopharmaceutical companies and academic institutions to advance the development of individual therapeutic approaches. Freeline Therapeutics has three main areas: hemophilia, Krabbe disease, and Fabry disease. In the hemophilia division, Freeline Therapeutics develops gene therapies for patients with hemophilia A and B. The therapy aims to improve the production of the missing clotting factor in the body. Such therapy could reduce or even eliminate the need for repeated infusions required to treat bleeding. In the Krabbe disease division, Freeline Therapeutics is developing a gene therapy for the treatment of Krabbe disease, a rare and life-threatening inherited disorder that affects the central nervous system. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain lipid compounds, thereby slowing down or even stopping the disease. In the Fabry disease division, Freeline Therapeutics is working on developing a gene therapy for the treatment of Fabry disease, a rare disorder that affects the cardiovascular system and other organs. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain fats, thereby slowing down or even stopping the disease. Freeline Therapeutics has several products in development, including FLT180a, FLT190a, and FLT200, all of which represent gene therapies for different rare diseases. FLT180a is a gene therapy being developed for the treatment of hemophilia A. FLT190a is a gene therapy being developed for the treatment of Krabbe disease. FLT200 is a gene therapy being developed for the treatment of Fabry disease. Freeline Therapeutics also has a pipeline of gene therapies currently in the preclinical phase. The company is committed to accelerating the development of gene therapies for rare diseases and improving patients' access to these innovative treatments. Overall, Freeline Therapeutics is an emerging biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company has expertise in AAV vector technology and aims to develop innovative and life-saving therapies for patients with rare diseases. Freeline Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Freeline Therapeutics Holdings's Return on Assets (ROA)

Freeline Therapeutics Holdings's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Freeline Therapeutics Holdings's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Freeline Therapeutics Holdings's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Freeline Therapeutics Holdings’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Freeline Therapeutics Holdings Stock

What is the Return on Assets (ROA) of Freeline Therapeutics Holdings this year?

The Return on Assets (ROA) of Freeline Therapeutics Holdings is -1.03 undefined this year.

What was the ROA of Freeline Therapeutics Holdings compared to the previous year?

The ROA of Freeline Therapeutics Holdings has increased by 3.26% compared to the previous year.

What consequences do high ROA have for investors of Freeline Therapeutics Holdings?

A high ROA is advantageous for investors of Freeline Therapeutics Holdings, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Freeline Therapeutics Holdings?

A low ROA can be unfavorable for investors of Freeline Therapeutics Holdings as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Freeline Therapeutics Holdings affect the company?

An increase in ROA of Freeline Therapeutics Holdings can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Freeline Therapeutics Holdings impact the company?

A reduction in the ROA of Freeline Therapeutics Holdings can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Freeline Therapeutics Holdings?

Some factors that can influence the ROA of Freeline Therapeutics Holdings include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Freeline Therapeutics Holdings important for investors?

The ROA of Freeline Therapeutics Holdings is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Freeline Therapeutics Holdings take to improve ROA?

To improve ROA, Freeline Therapeutics Holdings can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Freeline Therapeutics Holdings pay?

Over the past 12 months, Freeline Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Freeline Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Freeline Therapeutics Holdings?

The current dividend yield of Freeline Therapeutics Holdings is .

When does Freeline Therapeutics Holdings pay dividends?

Freeline Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Freeline Therapeutics Holdings?

Freeline Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Freeline Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Freeline Therapeutics Holdings located?

Freeline Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Freeline Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Freeline Therapeutics Holdings from 7/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.

When did Freeline Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 7/4/2024.

What was the dividend of Freeline Therapeutics Holdings in the year 2023?

In the year 2023, Freeline Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Freeline Therapeutics Holdings pay out the dividend?

The dividends of Freeline Therapeutics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Freeline Therapeutics Holdings

Our stock analysis for Freeline Therapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Freeline Therapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.